MIRA Pharmaceuticals Announces Initial Proof-Of-Concept Results From Pilot Study Of SKNY-1 For Obesity And Metabolic Disorders In A Diet-Induced Obesity Mouse Model; Study Demonstrated Statistically Significant Reductions In Body Weight And Fat Mass Following Oral Administration Of SKNY-1 Compared With Vehicle-Treated Controls
Key Findings From the SKNY-1 Pilot StudyStatistically Significant Weight and Fat ReductionOral SKNY-1 demonstrated statistically significant reductions in body weight and fat mass compared with vehicle-treated controls.
MIRA's new drug SKNY-1 helped mice lose weight in early tests. When a medicine works in mice, the company still needs to test it in people before anyone can use it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.